CCKBR and cancer: In another study, Qin et al. (2020) reported that the overexpression of cholecystokinin B receptor (CCKBR) in human cancers led to the development of radiolabelled minigastrin analogues for targeted radionuclide therapy, which aims to deliver cytotoxic radiation specifically to cancer cells [38].